Advances in Hematology / 2012 / Article / Tab 2

Review Article

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

Table 2

Ongoing clinical trials with rapalogs in patients with NHL.

PhaseLocationsClinical trial gov. numberAdditional information

I/IIUSANCT01076543Lenalidomide and Temsirolimus in patients with relapsed or refractory HL or NHL

I/IIUSANCT00787969Rituximab, Cladribe, and Temsirolimus in patients with newly diagnosed MCL

I/IIGERMANYNCT01078142Temsirolimus, Bendamustine, and Rituximab for relapsed FL or MCL (BERT)

I/IIUSANCT00474929Everolimus and sorafenib for relapsed or refractory NHL, HL, or MM

ICleveland OHNCT00671112Everolimus plus bortezomibe for relapsed/refractory MCL and other NHL

I/IIUSANCT00967044Panobinostat (LBH589) plus Everolimus (RAD001) in patients with relapsed and refractory Lymphoma

I/IIUSANCT 101075321Everolimus and Lenalidomide in treating patients with relapsed or refractory NHL or HL

I/IIUSANCT00918333Panobinostat and Everolimus in treating patients with recurrent MM, NHL, or HL

IIUSANCT00869999Everolimus plus Rituximab for relapsed/refractory DLBCL

I/IIUSANCT00704054Deferolimus for relapsed/refractory NHL/HL

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.